DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
DSS (NYSE American: DSS) announced that Impact Biomedical completed its business combination with Zoar Limited and Zoar Labs Limited. DSS had held a majority ownership interest in Impact Biomedical, which became a wholly owned subsidiary of Zoar Limited and was renamed Zoar USA. Each outstanding Impact Biomedical common share converted into the right to receive one Zoar Limited ordinary share.
Impact Biomedical stockholders approved the deal on November 13, 2026. Zoar Limited shares are expected to begin trading on November 18, 2026, on NYSE American under ZOAR. DSS retains its DSS ticker and will provide further details on the deal’s effect on its holdings and financial reporting through SEC filings, as appropriate.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Completed business combination moves DSS’s Impact Biomedical investment into a structure whose parent shares are expected to trade publicly.
Negative
- None.
News Explained
For the fiscal year ended
Key Figures
- Revenue
- approximately $651.7 million
- Zoar Labs, fiscal year ended March 31, 2026
- Net income
- $77.7 million
- Zoar Labs, fiscal year ended March 31, 2026
- Revenue growth
- approximately 17.1%
- Zoar Labs, year over year for fiscal year ended March 31, 2026
- Net income growth
- approximately 23.9%
- Zoar Labs, year over year for fiscal year ended March 31, 2026
- Share exchange ratio
- 1 ordinary share for each outstanding Impact Biomedical common share
- Transaction terms upon completion
- Expected trading date
- November 18, 2026
- Zoar Limited ordinary shares expected to begin trading on NYSE American under ZOAR
Previous Acquisition Reports
-
SEC effectiveness advanced the same Zoar combination; closing still awaited stockholder and listing approvals.
-
Zoar's Form F-4 filing began the same transaction's SEC review and shareholder-approval process.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
active pharmaceutical ingredients technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WEST HENRIETTA, NY / ACCESS Newswire / November 18, 2026 / DSS, Inc. (NYSE American:DSS) ("DSS" or the "Company") today announced that Impact Biomedical Inc. ("Impact Biomedical"), in which DSS has held a majority ownership interest, has completed its previously announced business combination with Zoar Limited ("Zoar") and Zoar Labs Limited ("Zoar Labs").
The business combination was approved by Impact Biomedical stockholders at a special meeting on November 13, 2026. Following completion, Impact Biomedical became a wholly owned subsidiary of Zoar Limited and was renamed Zoar USA Inc. Each outstanding share of Impact Biomedical common stock was converted into the right to receive one ordinary share of Zoar Limited, pursuant to the transaction terms.
Zoar Limited ordinary shares are expected to begin trading on the NYSE American under the ticker symbol "ZOAR" on November 18, 2026. The completion of the transaction provides a new publicly traded structure for the business and represents an important milestone in DSS's investment history with Impact Biomedical.
Jason Grady, Chief Executive Officer of DSS, commented:
"The successful completion of this transaction is a meaningful milestone for DSS and reflects our continued focus on advancing the potential of our portfolio investments. Through Impact Biomedical, DSS has supported the pursuit of opportunities intended to create long-term shareholder value. The combination with Zoar introduces an established international pharmaceutical operating business to the public markets and provides a new platform for future growth. We believe this development represents an important step in the evolution of our investment and reinforces our commitment to strategic transactions that can strengthen DSS's long-term position and create opportunities for our shareholders."
Zoar is a global pharmaceutical company focused on the development, manufacturing, and distribution of active pharmaceutical ingredients (APIs) and intermediates, as well as contract development and manufacturing services. Zoar Labs reported approximately
The transaction does not change DSS's NYSE American ticker symbol, "DSS." DSS will provide additional information concerning the transaction's impact on its investment holdings and financial reporting, as appropriate, through its SEC filings.
About DSS, Inc.
DSS, Inc. (NYSE American:DSS) is a diversified company with interests across multiple business sectors. For additional information, visit www.dssworld.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements concerning the expected commencement of trading of Zoar Limited ordinary shares, Zoar's business prospects, the potential benefits of the business combination, and potential long-term benefits to DSS and its shareholders. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including market and trading conditions, the ability of Zoar to maintain its listing and execute its business strategy, regulatory and operational risks, and uncertainties relating to DSS's investment and financial reporting. Additional risks are described in DSS's filings with the Securities and Exchange Commission and in filings relating to the business combination. Forward-looking statements speak only as of the date hereof, and DSS undertakes no obligation to update them except as required by law.
Investor Relations
DSS, Inc. | ir@dssworld.com
www.dssworld.com
SOURCE: DSS, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.